The HER2 inhibitors market consists of sales of HER2 inhibitors and related services by entities (organizations, sole traders, and partnerships) that manufacture HER2 inhibitors. Human epidermal growth factor receptor (HER2) inhibitors slow down or stop cell growth thus reducing the risk for cancer growth.
The global HER2 inhibitors market is expected to decline from $6.21 billion in 2019 to $6.07 billion in 2020 at a compound annual growth rate (CAGR) of -2.19%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of several activities resulting in operational challenges. The market is then expected to recover and reach $8.29 billion in 2023 at a CAGR of 10.96%.
